You are here

  • Home
  • Archive
  • Volume 73, Issue 8
  • Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’

Article Text

Article menu
Download PDFPDF
PostScript
Comment on ‘Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy’

https://doi.org/10.1136/jclinpath-2019-206366

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Handling editor Runjan Chetty.

    • Contributors All authors contributed to the writing of the manuscript.

    • Funding This study was funded by Fondation ARC pour la Recherche sur le Cancer, France (grant number:PDF20171206738).

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.